Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals, Inc. | 2026-09-08 14:59:59 | 22.94 | -0.24 | -1.06 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMPH | 0001297184 | Amphastar Pharmaceuticals, Inc. | US03209R1032 | 54930055TH0ZLSAQMJ38 | 330702205 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | — | 11570 SIXTH STREET | RANCHO CUCAMONGA | CA | 91730 | UNITED STATES | US | 909-980-9484 | 11570 SIXTH STREET, RANCHO CUCAMONGA, CA, 91730 | 11570 SIXTH STREET, RANCHO CUCAMONGA, CA, 91730 | — | — | — | Jack Yongfeng Zhang | 1,615 | https://www.amphastar.com/ | 632,556,518 | 62,306,254 | 42,537,944 | Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. | 2026-09-03 20:36:34 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 632,556,518 | -565,210,602 | -47.1887 | 45,370,171 | -2,279,950 | -4.7848 |
| 2024 | 1,197,767,120 | -289,349,473 | -19.4571 | 47,650,121 | -445,741 | -0.9268 |
| 2023 | 1,487,116,593 | 601,855,576 | 67.9862 | 48,095,862 | 199,042 | 0.4156 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Mary Ziping Luo | Chief Scientist, Chief Operating Officer, Chairman | 2025 | 775,120 | 288,923 | 1,391,976 | 128,000 | 55,029 | 4,031,078 |
| Rong Zhou | President, Executive Vice President | 2025 | 717,587 | 280,475 | 701,500 | 98,000 | 43,559 | 2,542,634 |
| Jack Yongfeng Zhang | Chief Executive Officer, President, Chief Scientific Officer, Director | 2025 | 950,911 | 329,747 | 3,301,981 | 361,000 | 63,687 | 8,309,350 |
| William J. Peters | Executive Vice President, Director, President, Chief Financial Officer, Treasurer | 2025 | 649,846 | 370,308 | 1,043,982 | 73,000 | 57,524 | 3,238,682 |
| Jacob Liawatidewi | President, Executive Vice President | 2025 | 499,909 | 265,200 | 591,979 | 47,000 | 41,742 | 2,037,856 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 1,976 |
| 2024 | 2,028 |
| 2023 | 1,761 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 719,887,000 | 731,967,000 | 644,395,000 |
| Cost Of Revenue | 363,830,000 | 358,112,000 | 293,274,000 |
| Gross Profit | 356,057,000 | 373,855,000 | 351,121,000 |
| Research And Development Expenses | 85,844,000 | 73,914,000 | 73,741,000 |
| General And Administrative Expenses | 85,925,000 | 56,720,000 | 51,540,000 |
| Operating Expenses | 215,654,000 | 168,436,000 | 154,134,000 |
| Operating Income | 140,403,000 | 205,419,000 | 196,987,000 |
| Net Income | 98,094,000 | 159,519,000 | 137,545,000 |
| Earnings Per Share Basic | 2.1 | 3.29 | 2.85 |
| Earnings Per Share Diluted | 2.03 | 3.06 | 2.6 |
| Weighted Average Shares Outstanding Basic | 46,743,000 | 48,429,000 | 48,265,000 |
| Weighted Average Shares Outstanding Diluted | 48,215,000 | 52,058,000 | 53,001,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 170,177,000 | 151,609,000 | 144,296,000 |
| Marketable Securities Current | 112,635,000 | 70,036,000 | 112,510,000 |
| Accounts Receivable | 143,560,000 | 136,289,000 | 114,943,000 |
| Inventories | 176,890,000 | 153,741,000 | 105,833,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 13,152,000 | 18,214,000 | 9,057,000 |
| Total Assets Current | 636,016,000 | 534,071,000 | 489,600,000 |
| Marketable Securities Non Current | — | 10,996,000 | 14,685,000 |
| Property Plant And Equipment | 310,567,000 | 297,345,000 | 282,746,000 |
| Other Assets Non Current | 31,135,000 | 25,992,000 | 25,910,000 |
| Total Assets Non Current | 353,719,000 | 344,627,000 | 894,662,000 |
| Total Assets | 1,629,299,000 | 1,577,470,000 | 1,512,912,000 |
| Accounts Payable | 32,592,000 | 30,514,000 | 25,438,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 1,641,000 | 234,000 | 436,000 |
| Other Liabilities Current | 115,756,000 | 126,543,000 | 67,928,000 |
| Total Liabilities Current | 158,156,000 | 173,759,000 | 225,407,000 |
| Long Term Debt | 608,749,000 | 601,630,000 | 589,579,000 |
| Other Liabilities Non Current | 29,979,000 | 20,945,000 | 22,718,000 |
| Total Liabilities Non Current | 682,338,000 | 671,413,000 | 648,084,000 |
| Total Liabilities | 840,494,000 | 845,172,000 | 873,491,000 |
| Common Stock | 6,000 | 6,000 | 6,000 |
| Retained Earnings | 666,881,000 | 568,787,000 | 409,268,000 |
| Accumulated Other Comprehensive Income | -5,314,000 | -9,181,000 | -8,478,000 |
| Total Shareholders Equity | 788,805,000 | 732,298,000 | 639,421,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 31,647,000 | 28,249,000 | 25,737,000 |
| Share Based Compensation Expense | 27,277,000 | 24,368,000 | 20,242,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 6,367,000 | 21,671,000 | 26,086,000 |
| Change In Inventories | 21,063,000 | 48,797,000 | 1,724,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 3,530,000 | 10,726,000 | 2,728,000 |
| Change In Accounts Payable | -4,559,000 | 63,563,000 | 13,237,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 156,115,000 | 213,386,000 | 183,503,000 |
| Purchases Of Marketable Securities | 119,130,000 | 76,792,000 | 144,556,000 |
| Sales Of Marketable Securities | 90,291,000 | 126,022,000 | 38,622,000 |
| Acquisition Of Property Plant And Equipment | 34,882,000 | 41,041,000 | 38,166,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -70,332,000 | -124,930,000 | -649,116,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 2,855,000 | — | 10,974,000 |
| Repurchase Of Common Stock | 75,586,000 | 85,458,000 | 58,144,000 |
| Issuance Of Long Term Debt | — | — | 845,000,000 |
| Repayment Of Long Term Debt | 223,000 | 8,263,000 | 318,658,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -67,425,000 | -80,953,000 | 454,093,000 |
| Change In Cash | 18,568,000 | 7,313,000 | -11,802,000 |
| Cash At End Of Period | 170,177,000 | 151,609,000 | 144,296,000 |
| Income Taxes Paid | 22,710,000 | 40,104,000 | 49,001,000 |
| Interest Paid | 23,218,000 | 26,811,000 | 17,573,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 2.1 | 3.29 | 2.85 |
| Price To Earnings Ratio | 12.7524 | 11.2857 | 21.7018 |
| Earnings Growth Rate | -36.1702 | 15.4386 | 51.5957 |
| Price Earnings To Growth Ratio | -0.3526 | 0.731 | 0.4206 |
| Book Value Per Share | 16.8754 | 15.1211 | 13.2481 |
| Price To Book Ratio | 1.5869 | 2.4555 | 4.6686 |
| Ebitda | 177,932,000 | 258,215,000 | 239,441,000 |
| Enterprise Value | 1,691,990,540 | 2,248,423,770 | 3,430,909,250 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.7738 | 0.8219 | 0.9227 |
| Capital Expenditures | 44,869,000 | 42,848,000 | 70,217,000 |
| Free Cash Flow | 111,246,000 | 170,538,000 | 113,286,000 |
| Return On Equity | 0.1244 | 0.2178 | 0.2151 |
| One Year Beta | 0.7187 | 0.6487 | 0.803 |
| Three Year Beta | 0.7227 | 0.5478 | 0.5261 |
| Five Year Beta | 0.5848 | 0.678 | 0.7095 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER | 2026-09-02 | 3,187 | D | 169,203 |
| PRINS RICHARD K | Director | 2026-08-11 | 7,973 | D | 29,625 |
| PETERS WILLIAM J | Director, CFO, EVP & TREASURER | 2026-08-07 | 5,053 | A | 181,026 |
| PETERS WILLIAM J | Director, CFO, EVP & TREASURER | 2026-08-07 | 8,180 | D | 172,846 |
| PETERS WILLIAM J | Director, CFO, EVP & TREASURER | 2026-08-07 | 5,053 | D | 0 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Parkside Financial Bank & Trust | 2026-06-30 | 2,160 | 107 | 20.1869 |
| BROWN, LISLE/CUMMINGS, INC. | 2026-06-30 | 545 | 27 | 20.1852 |
| CITADEL ADVISORS LLC | 2026-06-30 | 209,872 | 10,400 | 20.18 |
| CITADEL ADVISORS LLC | 2026-06-30 | 327,542 | 16,231 | 20.18 |
| CITADEL ADVISORS LLC | 2026-06-30 | 221,980 | 11,000 | 20.18 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Vericimetry Funds | 2026-06-30 | Vericimetry U.S. Small Cap Value Fund | VYSVX | 1,450 | 29,261 | 0.0158 |
| STERLING CAPITAL FUNDS | 2026-06-30 | Class R6 | STRBX | 9,261 | 186,886.98 | 0.232 |
| STERLING CAPITAL FUNDS | 2026-06-30 | Class C | SPSDX | 9,261 | 186,886.98 | 0.232 |
| STERLING CAPITAL FUNDS | 2026-06-30 | Class A | SPSAX | 9,261 | 186,886.98 | 0.232 |
| STERLING CAPITAL FUNDS | 2026-06-30 | INSTITUTIONAL SHARES | SPSCX | 9,261 | 186,886.98 | 0.232 |